Ocugen licenses OCU400 to Celairis for Australia, New Zealand and ASEAN marketsNov 10PartnershipOCU400Ocugen
Ocugen reports Bahamas regulatory progress and MENA license for OCU400 in Q3 updateNov 4Quarterly updateOCU400OCU410
Ocugen licenses OCU400 gene therapy to Roots Pharmaceutical for MENA regionOct 14PartnershipOCU400Ocugen
Ocugen registers Phase 3 trial of OCU410 gene therapy for geographic atrophy in dry AMDAug 18Trial updateOCU410Ocugen
Ocugen reports Q2 2026 update with FDA clearance for OCU410 Phase 3 and $130M raiseAug 6Quarterly updateOCU400OCU410